Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis.
Thirteen psoriatic patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs. Seven of the 13 patients had exhibited a subclinical hypertensive state before cyclosporin A therapy. Both systolic and diastolic blood pressures of these 13 patients were decreased significantly after 4 weeks of nifedipine therapy, and blood pressure was maintained within the normal range thereafter for 25 months. The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in blood urea nitrogen levels in 9 of the 13 patients and development of gingival hyperplasia in 2 of the 13 patients. Our findings indicate that sustained-release nifedipine is useful for hypertensive psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia.
Nakayama
J
J
Department of Dermatology, Fukuoka University School of Medicine, 7-45-1, Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan.
Koga
T
T
Furue
M
M
D000328:Adult; D000368:Aged; D001795:Blood Pressure Determination; D002121:Calcium Channel Blockers / Q000008:administration & dosage* / Q000009:adverse effects*; D016572:Cyclosporine / Q000009:adverse effects* / Q000627:therapeutic use; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005885:Gingival Hyperplasia / Q000139:chemically induced; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced; D006973:Hypertension / Q000139:chemically induced / Q000188:drug therapy*; D007677:Kidney Function Tests; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000008:administration & dosage* / Q000009:adverse effects*; D011565:Psoriasis / Q000188:drug therapy*; D016896:Treatment Outcome
D002121:Calcium Channel Blockers; D003692:Delayed-Action Preparations; D016572:Cyclosporine; D009543:Nifedipine